PPM1G Inhibits Epithelial–Mesenchymal Transition in Cholangiocarcinoma by Catalyzing TET1 Dephosphorylation for Destabilization to Impair Its Targeted Demethylation of the CLDN3 Promoter
2024

PPM1G Inhibits Epithelial–Mesenchymal Transition in Cholangiocarcinoma

Sample size: 36 publication 10 minutes Evidence: high

Author Information

Author(s): W. Liu, Y. Kuai, D. Wang, J. Chen, F. Xiong, G. Wu, Q. Wang, W. Huang, Y. Qi, B. Wang, Y. Chen

Primary Institution: Tongji Medical College Huazhong University of Science and Technology

Hypothesis

PPM1G catalyzes the dephosphorylation of TET1, impairing its targeted demethylation of the CLDN3 promoter.

Conclusion

PPM1G can be targeted therapeutically to impede cholangiocarcinoma progression by destabilizing TET1 and inhibiting its function.

Supporting Evidence

  • TET1 is highly expressed in cholangiocarcinoma and correlates with poor prognosis.
  • PPM1G destabilizes TET1, impairing its ability to promote CLDN3 transcription.
  • Phosphatase inhibitors can reduce TET1 levels and inhibit cholangiocarcinoma cell proliferation.
  • Combination therapy with phosphatase inhibitors and TET1 inhibitors shows enhanced efficacy in inhibiting cancer progression.

Takeaway

This study shows that a protein called PPM1G can help stop cancer cells from spreading by making another protein, TET1, less stable.

Methodology

The study utilized immunohistochemical analysis, RNA sequencing, and various in vitro and in vivo experiments to assess the role of TET1 and PPM1G in cholangiocarcinoma.

Participant Demographics

Patients with cholangiocarcinoma, with a sample size of 36 cancer tissues and 9 normal tissues.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1002/advs.202407323

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication